Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for antibody-drug conjugates.

Septerna, Inc. (NASDAQ:SEPN) is one of the best up and coming stocks on our list. TheFly reported on June 11 that Guggenheim ...

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

Discover Prague's biotech hub, now viewed as the primary ‘entry gateway’ into the wider Central and Eastern European ...

Swiss pharma heavyweight Novartis is cutting a very large check. The company has agreed to acquire London-headquartered ...

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

Novartis is buying Myricx to internalize an NMTi-based ADC payload platform intended to expand ADC applicability and ...

Study demonstrates application of DNA-Encoded Library screening to native-like membrane protein targets with the ...

"I've never been to Korea personally, but our portfolio has not missed a single innovative technology from the country. We ...

After earning her biochemistry and biotechnology bachelor’s, Allison Lendman is staying at UMSL in an accelerated master’s ...

PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class ...

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.